These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38431260)

  • 1. Evaluation of consumer self-selection of a proposed over-the-counter, progestin-only daily oral contraceptive.
    Sober S; Bradford R; Henrie B; Pradeau S; Guillard H; Laurora I; Glasier A
    Contraception; 2024 May; 133():110401. PubMed ID: 38431260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of adherence to a daily progestin-only pill in a simulated over-the-counter setting.
    Laurora I; Henrie B; Guillard H; Bradford R; Sober S; Glasier A
    Contraception; 2024 May; 133():110388. PubMed ID: 38431261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Norgestrel (Opill) Is the First Over-the-Counter Oral Contraceptive Pill Approved in the United States.
    Shiroff J
    Nurs Womens Health; 2024 Apr; 28(2):148-151. PubMed ID: 38346681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the potential benefit of an over-the-counter progestin-only pill in preventing unintended pregnancies in the U.S.
    Guillard H; Laurora I; Sober S; Karapet A; Brass EP; Glasier A
    Contraception; 2023 Jan; 117():7-12. PubMed ID: 36257375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of deliberate non-adherence to a norgestrel progestin-only pill: A randomized, crossover study.
    Glasier A; Edelman A; Creinin MD; Brache V; Westhoff CL; Han L; Chen MJ; Hemon A
    Contraception; 2023 Jan; 117():1-6. PubMed ID: 36130667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desogestrel, norgestimate, and gestodene: the newer progestins.
    Kaplan B
    Ann Pharmacother; 1995; 29(7-8):736-42. PubMed ID: 8520092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study.
    Burchardt NA; Eliassen AH; Shafrir AL; Rosner B; Tamimi RM; Kaaks R; Tworoger SS; Fortner RT
    Am J Obstet Gynecol; 2022 Jun; 226(6):821.e1-821.e26. PubMed ID: 34921803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of a progestin-only oral contraceptive versus non-hormonal methods in lactating women in Buenos Aires, Argentina.
    Moggia AV; Harris GS; Dunson TR; Diaz R; Moggia MS; Ferrer MA; McMullen SL
    Contraception; 1991 Jul; 44(1):31-43. PubMed ID: 1893700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progestin-only oral contraception: a comprehensive review.
    McCann MF; Potter LS
    Contraception; 1994 Dec; 50(6 Suppl 1):S1-195. PubMed ID: 10226677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of a 0.075 mg norgestrel progestogen-only pill 2. Effect on cervical mucus and theoretical risk of conception.
    Han L; Creinin MD; Hemon A; Glasier A; Chen MJ; Edelman A
    Contraception; 2022 Aug; 112():43-47. PubMed ID: 35367204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exogenous progestins and breast cancer.
    Stanford JL; Thomas DB
    Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A norgestimate-containing oral contraceptive: review of clinical studies.
    Kafrissen ME
    Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study.
    Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B
    Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral contraceptives and cardiovascular risk. Taking a safe course of action.
    Derman RJ
    Postgrad Med; 1990 Sep; 88(4):119-22. PubMed ID: 2204902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of progestins on adverse effects of oral contraceptives].
    Wynn V
    Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and risks of oral contraceptive use.
    Williams RS
    Postgrad Med; 1992 Nov; 92(7):155-7, 161-2, 168-71. PubMed ID: 1437913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opill: The Over-the-Counter Contraceptive Pill.
    Allen RH; Bartz D
    Obstet Gynecol; 2024 Feb; 143(2):184-188. PubMed ID: 37944139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation.
    Jeng MH; Parker CJ; Jordan VC
    Cancer Res; 1992 Dec; 52(23):6539-46. PubMed ID: 1423300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.